Twist Bioscience (NASDAQ: TWIST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced on 5/6/19 that it has commenced... read more
Twist Bioscience (NASDAQ: TWIST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced on 5/6/19 that it has commenced... read more
Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced on 4/30/19 that data demonstrating its... read more
Triumvira, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, has simultaneously submitted an IND to the U.S. Food and Drug... read more
Clinical-stage biopharmaceutical company, NextCure, has updated its filing for an IPO to raise up to $93 million. The company has applied to trade on NASDAQ under the symbol, "NXTC”.
... read more
AOBiome Featured in Bloomberg Businessweek
It was a snowy week in February 2009 when David Whitlock packed up... read more